Trial Profile
Clinical Assessment of GSK716155 [albiglutide] for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors GSK
- 01 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
- 09 Jun 2009 This study was published as an abstract in the proceedings of the 69th Annual Scientific Sessions of the American Diabetes Association.
- 27 Oct 2008 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.